President Donald Trump has signed an executive order directing federal agencies to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act, marking one of the most consequential shifts in U.S. cannabis policy in more than 50 years. While the move stops short of federal legalization, it formally acknowledges marijuana’s medical value and lower abuse potential.
For the cannabis edibles and infused beverage market, the implications are significant.
Moving cannabis to Schedule III eases federal restrictions that have long limited research and development. This change allows for more scientific study into how cannabis behaves when ingested—particularly important for edibles and drinks, where dosing accuracy, onset time, and consistency are critical to consumer safety and satisfaction.
The rescheduling also provides financial relief for state-licensed cannabis businesses by allowing them to access federal tax deductions previously blocked under IRS code 280E. Over time, this could support higher manufacturing standards, improved labeling, and increased innovation across edible and beverage categories.
In addition, the executive order includes a directive to address federal hemp laws and explore broader access to full-spectrum CBD. A proposed pilot program would allow Medicare recipients to be reimbursed for non-intoxicating CBD products, a move that could further legitimize CBD-infused beverages and functional wellness drinks.
Although cannabis remains regulated at the state level and THC edibles are still prohibited in some states, federal rescheduling signals a clear shift toward normalization. For consumers, this development points to a future of better-researched, more reliable, and increasingly accepted cannabis edibles and drinks.